Table 1.

Clinicopathologic characteristics of the 24 INSPIRE patients used in this analysis

GenderAge at time of first pembrolizumab infusion (years)EthnicityTumor typeNumber of pembrolizumab infusionsReason for stopping pembrolizumabirAEBest responseLength of follow-up (days)Dead or alive
TypeGrade
Group A (−) response (−) toxicity
 Female50.4Black or African AmericanTNBC5ProgressionNoneN/APD631Dead
 Female35.5AsianTNBC3ProgressionNoneN/APD435Dead
 Female73.5WhiteTNBC3ProgressionNoneN/APD142Dead
 Female66.7WhiteHGSO5Clinical progressionNoneN/APD494Dead
 Female72.9WhiteHGSO4ProgressionNoneN/APD505Alive
 Male74.1WhiteMelanoma5ProgressionNoneN/APD196Dead
Group B (−) response (+) toxicity
 Male58.0WhiteMelanoma5ProgressionHypothyroidism2PD187Dead
 Female49.4WhiteHGSO3ProgressionAbdominal pain2PD564Dead
Arthralgia2
Flu-like symptoms2
 Female53.5WhiteHGSO2ProgressionHypothyroidism2PD461Dead
 Female44.8WhiteHGSO3ProgressionDiarrhea2PD133Dead
 Male27.9WhiteSarcoma, granular cell5ProgressionRash (on 2 separate occasions)2PD613Dead
 Male51.5WhiteCholangiocarcinoma6ProgressionHypothyroidism2PD289Alive
Group C (+) response (+) toxicity
 Male70.5WhiteHNSCC20ToxicityALT elevation3CR856Alive
AST elevation2
Hepatitis2
Lipase increase3
Rash2
 Male61.4WhiteMelanoma28Clinical progressionLipase increased3PR644Alive
Pancreatitis2
 Male73.1WhiteMelanoma35Study completionHypothyroidism2PR526Alive
Rash2
 Male70.1WhiteMelanoma21Intercurrent illnessColitis3PR731Alive
Pneumonitis2
Rash2
 Female53.8WhiteMelanoma31Still on trialHypothyroidism2PR630Alive
 Female54.5WhiteMelanoma23Still on trialHyperthyroidism2PR488Alive
Hypothyroidism2
 Male70.7WhiteMerkel cell carcinoma16ToxicityPneumonitis3PR578Dead
 Male50.0WhiteBasal cell and squamous cell poorly differentiated carcinoma16ToxicityColitis3PR621Alive
Group D (+) response (−) toxicity
 Female61.3WhiteTNBC27Still on trialNoneN/APR546Alive
 Female67.8WhiteMelanoma35Study completionNoneN/APR782Alive
 Female45.0WhiteMelanoma25ProgressionNoneN/APR517Alive
 Male74.7WhiteMerkel cell carcinoma21ProgressionNoneN/APR578Alive
  • Last clinical outcome update November 14, 2018.

  • Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CR, complete response; HGSO, high-grade serous ovarian carcinoma; HNSCC, head and neck squamous cell carcinoma; PD, progressive disease; PR, partial response; TNBC, triple-negative breast cancer.